Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11787851 Optimized factor VIII gene

Patent 11787851 was granted and assigned to Bioverativ on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
‌
Bioverativ
Date Filed
June 25, 2019
Date of Patent
October 17, 2023
Patent Applicant
‌
Bioverativ
Patent Application Number
16452010
Patent Citations
‌
US Patent 8734809 AAV's and uses thereof
‌
US Patent 9050269 Protection of virus particles from phagocytosis by expression of CD47
‌
US Patent 9050318 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
‌
US Patent 9061059 Modified polynucleotides for treating protein deficiency
‌
US Patent 9169491 Virus purification
‌
US Patent 10000748 Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
‌
US Patent 10058624 Recombinant promoters and vectors for protein expression in liver and use thereof
‌
US Patent 10370431 Optimized factor VIII gene
‌
US Patent 10125357 Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
‌
US Patent 7179903 Liver specific transcriptional enhancer
•••
Patent Inventor Names
Siyuan Tan
Robert T. Peters
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11787851
Patent Primary Examiner
‌
Michael Szperka

Find more entities like US Patent 11787851 Optimized factor VIII gene

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.